257 related articles for article (PubMed ID: 22661948)
41. Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice.
Ruddy KJ; Desantis SD; Gelman RS; Wu AH; Punglia RS; Mayer EL; Tolaney SM; Winer EP; Partridge AH; Burstein HJ
Breast Cancer Res Treat; 2013 Oct; 141(3):421-7. PubMed ID: 24062210
[TBL] [Abstract][Full Text] [Related]
42. Nonlinear Mixed-Effects Model of Z-Endoxifen Concentrations in Tamoxifen-Treated Patients from the CEPAM Cohort.
Mc Laughlin AM; Helland T; Klima F; Koolen SLW; van Schaik RHN; Mathijssen RHJ; Neven P; Swen JJ; Guchelaar HJ; Dalenc F; White-Koning M; Michelet R; Mikus G; Schroth W; Mürdter T; Brauch H; Schwab M; Søiland H; Mellgren G; Thomas F; Kloft C; Hertz DL;
Clin Pharmacol Ther; 2024 Mar; ():. PubMed ID: 38494911
[TBL] [Abstract][Full Text] [Related]
43. Increasing tamoxifen dose in breast cancer patients based on CYP2D6 genotypes and endoxifen levels: effect on active metabolite isomers and the antiestrogenic activity score.
Barginear MF; Jaremko M; Peter I; Yu C; Kasai Y; Kemeny M; Raptis G; Desnick RJ
Clin Pharmacol Ther; 2011 Oct; 90(4):605-11. PubMed ID: 21900890
[TBL] [Abstract][Full Text] [Related]
44. Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity.
Ahern TP; Hertz DL; Damkier P; Ejlertsen B; Hamilton-Dutoit SJ; Rae JM; Regan MM; Thompson AM; Lash TL; Cronin-Fenton DP
Am J Epidemiol; 2017 Jan; 185(2):75-85. PubMed ID: 27988492
[TBL] [Abstract][Full Text] [Related]
45. Individualization of tamoxifen therapy: much more than just CYP2D6 genotyping.
Binkhorst L; Mathijssen RH; Jager A; van Gelder T
Cancer Treat Rev; 2015 Mar; 41(3):289-99. PubMed ID: 25618289
[TBL] [Abstract][Full Text] [Related]
46. Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma.
Mürdter TE; Schroth W; Bacchus-Gerybadze L; Winter S; Heinkele G; Simon W; Fasching PA; Fehm T; ; Eichelbaum M; Schwab M; Brauch H
Clin Pharmacol Ther; 2011 May; 89(5):708-17. PubMed ID: 21451508
[TBL] [Abstract][Full Text] [Related]
47. Boronic prodrug of endoxifen as an effective hormone therapy for breast cancer.
Zhang C; Zhong Q; Zhang Q; Zheng S; Miele L; Wang G
Breast Cancer Res Treat; 2015 Jul; 152(2):283-91. PubMed ID: 26071758
[TBL] [Abstract][Full Text] [Related]
48. Impact of Curcumin (with or without Piperine) on the Pharmacokinetics of Tamoxifen.
Hussaarts KGAM; Hurkmans DP; Oomen-de Hoop E; van Harten LJ; Berghuis S; van Alphen RJ; Spierings LEA; van Rossum-Schornagel QC; Vastbinder MB; van Schaik RHN; van Gelder T; Jager A; van Leeuwen RWF; Mathijssen RHJ
Cancers (Basel); 2019 Mar; 11(3):. PubMed ID: 30909366
[TBL] [Abstract][Full Text] [Related]
49. Model-Based Quantification of Impact of Genetic Polymorphisms and Co-Medications on Pharmacokinetics of Tamoxifen and Six Metabolites in Breast Cancer.
Puszkiel A; Arellano C; Vachoux C; Evrard A; Le Morvan V; Boyer JC; Robert J; Delmas C; Dalenc F; Debled M; Venat-Bouvet L; Jacot W; Dohollou N; Bernard-Marty C; Laharie-Mineur H; Filleron T; Roché H; Chatelut E; Thomas F; White-Koning M
Clin Pharmacol Ther; 2021 May; 109(5):1244-1255. PubMed ID: 33047329
[TBL] [Abstract][Full Text] [Related]
50. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen.
Johnson MD; Zuo H; Lee KH; Trebley JP; Rae JM; Weatherman RV; Desta Z; Flockhart DA; Skaar TC
Breast Cancer Res Treat; 2004 May; 85(2):151-9. PubMed ID: 15111773
[TBL] [Abstract][Full Text] [Related]
51. Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study.
Irvin WJ; Walko CM; Weck KE; Ibrahim JG; Chiu WK; Dees EC; Moore SG; Olajide OA; Graham ML; Canale ST; Raab RE; Corso SW; Peppercorn JM; Anderson SM; Friedman KJ; Ogburn ET; Desta Z; Flockhart DA; McLeod HL; Evans JP; Carey LA
J Clin Oncol; 2011 Aug; 29(24):3232-9. PubMed ID: 21768473
[TBL] [Abstract][Full Text] [Related]
52. Integrated Data Analysis of Six Clinical Studies Points Toward Model-Informed Precision Dosing of Tamoxifen.
Klopp-Schulze L; Mueller-Schoell A; Neven P; Koolen SLW; Mathijssen RHJ; Joerger M; Kloft C
Front Pharmacol; 2020; 11():283. PubMed ID: 32296331
[TBL] [Abstract][Full Text] [Related]
53. Effects of
Charoenchokthavee W; Areepium N; Panomvana D; Sriuranpong V
Breast Cancer (Dove Med Press); 2017; 9():249-256. PubMed ID: 28450788
[TBL] [Abstract][Full Text] [Related]
54. CYP2D6 genotype and endoxifen plasma concentration do not predict hot flash severity during tamoxifen therapy.
Jansen LE; Teft WA; Rose RV; Lizotte DJ; Kim RB
Breast Cancer Res Treat; 2018 Oct; 171(3):701-708. PubMed ID: 29980881
[TBL] [Abstract][Full Text] [Related]
55. Association of CYP2D6*10 (c. 100 C>T) Genotype with Z-END Concentration in Patients with Breast Cancer Receiving Tamoxifen Therapy in Indonesian Population.
Yenny ; Panigoro SS; Purwanto DJ; Hidayat A; Louisa M; Andalusia R; Setiabudy R
Endocr Metab Immune Disord Drug Targets; 2019; 19(8):1198-1206. PubMed ID: 30843495
[TBL] [Abstract][Full Text] [Related]
56. Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
Punglia RS; Burstein HJ; Winer EP; Weeks JC
J Natl Cancer Inst; 2008 May; 100(9):642-8. PubMed ID: 18445827
[TBL] [Abstract][Full Text] [Related]
57. Dose-adjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients.
Kiyotani K; Mushiroda T; Imamura CK; Tanigawara Y; Hosono N; Kubo M; Sasa M; Nakamura Y; Zembutsu H
Breast Cancer Res Treat; 2012 Jan; 131(1):137-45. PubMed ID: 21947681
[TBL] [Abstract][Full Text] [Related]
58. Influence of CYP2D6 and CYP3A4 Phenotypes, Drug Interactions, and Vitamin D Status on Tamoxifen Biotransformation.
Antunes MV; Timm TA; de Oliveira V; Staudt DE; Raymundo S; Gössling G; Biazús JV; Cavalheiro JA; Rosa DD; Wallemacq P; Haufroid V; Linden R; Schwartsmann G
Ther Drug Monit; 2015 Dec; 37(6):733-44. PubMed ID: 25853922
[TBL] [Abstract][Full Text] [Related]
59. A pooled analysis of CYP2D6 genotype in breast cancer prevention trials of low-dose tamoxifen.
Johansson H; Gandini S; Serrano D; Gjerde J; Lattanzi M; Macis D; Guerrieri-Gonzaga A; Aristarco V; Mellgren G; Lien E; DeCensi A; Bonanni B
Breast Cancer Res Treat; 2016 Aug; 159(1):97-108. PubMed ID: 27484880
[TBL] [Abstract][Full Text] [Related]
60. Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients.
Helland T; Henne N; Bifulco E; Naume B; Borgen E; Kristensen VN; Kvaløy JT; Lash TL; Alnæs GIG; van Schaik RH; Janssen EAM; Hustad S; Lien EA; Mellgren G; Søiland H
Breast Cancer Res; 2017 Nov; 19(1):125. PubMed ID: 29183390
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
